Phase II trial of BNC105P as 2nd line chemotherapy for advanced malignant pleural mesothelioma.

Trial Profile

Phase II trial of BNC105P as 2nd line chemotherapy for advanced malignant pleural mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs BNC 105 (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms B2P2M2
  • Most Recent Events

    • 17 Apr 2015 According to a Bionomics media release, biomarker data from this trial will be presented as a part of a pooled analysis of this and two other trials at the American Association for Cancer Research (AACR) 106th Annual Meeting.
    • 20 Feb 2014 Status changed from active, no longer recruiting to completed, as per the Australian New Zealand Clinical Trials Registry record.
    • 03 Aug 2011 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top